MedTrace Logo

Long Term Follow-up Observational Study in Patients Treated with Gene-Modified T-Cell Therapy

NCT06825845 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2025-02-13

No results posted yet for this study

Summary

This is a prospective long-term follow-up (LTFU) study to evaluate the long-term safety and survival benefit for patients who received at least one of CARsgen's GM T cell product in a clinical trial or as a commercially available product. In this study, patients will be followed for up to 15 years after last GM T-cell infusion for the evaluation of delayed adverse events (AEs), vector persistence, potential risk for integration, and survival time due to GM T-cell exposure.

Conditions

Interventions

DRUG

Zevorcabtagene Autoleucel

Non-intervention

Sponsors & Collaborators

  • CARsgen Therapeutics Co., Ltd.

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-31
Primary Completion
2039-12-31
Completion
2040-06-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06825845 on ClinicalTrials.gov